Treatment

TransCon IL-2 ß/ү, TransCon TLR7/8 Agonist, KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
BelieveIT-201: A Randomized, Phase 2, Open-label Trial of TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
This study looks at new ways to treat a type of head and neck cancer before surgery. It's testing new medicines, alone or together, to see if they can shrink the cancer effectively. This could help improve treatment for people with this specific cancer.
For: Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Spain · Hungary · Poland